Summit Therapeutics Inc. in 2 stories

Western drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.

Summit holds major ex-China rights to Akeso's ivonescimab and is the clearest Western-listed vehicle for commercializing one of China's most closely watched oncology molecules.

Large drugmakers facing revenue holes must buy scarce pipelines, turning clinical validation into strategic currency.

Late-stage ivonescimab gives Summit a potentially differentiated oncology asset whose clinical validation materially strengthens its negotiating leverage.